Noveris Health Sciences is trading 9.09% up at CA$0.18, with the move appearing mainly supported by stronger biotechnology sentiment.
- No new company-specific announcement or reliable report was identified for August 25, 2026.
- The latest disclosure was an August 20 proposal for up to CA$500,000 in convertible debentures, expected to close around August 28.
- XBI rose 2.06% alongside broader gains in major U.S. indices; the company-specific catalyst remains unconfirmed.